Eric Lefkofsky has started many companies in the past. Groupon, Echo Global and InnerWorkings are examples of his work. InnerWorkings like Echo Global is now a global company. Working on e-‘commerce startups’ has made Eric a small fortune: $1.79 billion. Now Tempus is the company that occupies him and drains a good portion of his time and energy, not to mention industry. Tempus is about the composition of a genomic cancer database.
The idea is to help doctors treating cancer patients to get access to vital information on patient’s DNA and compare the same with other patients and then formulate an individualized treatment plan. This, according to the Tempus hypothesis will help patients live longer and others get cured.
The distinction between what other cancer centers are doing and what Tempus does is the partnership Tempus forges with leading hospitals. This partnership enables Tempus to gather data that is used for analysis. Tempus enables physician to compare their patients DNA and that of other patients in the database using software. This comparison helps doctors to learn from other successful cancer treatments of patients who had similar DNA with his/her current patient.
The decision by Eric Lefkofsky to step aside from his job at Groupon was triggered by his desire to concentrate on Tempus and the work it is doing. Although he no longer works as CEO at Groupon, Eric sits on the board and is a majority shareholder. Lefkofsky saw the need to introduce Kevin to Tempus for his expertise in genetics. Kevin has more than a decade health work experience in the area of genetics at ‘University of Chicago’.
Eric Lefkofsky and Brad Kevwell have been in business for a long time as partners. At Tempus they are equal partners.
Eric graduated from ‘University of Michigan’. He is an ‘adjust professor for ‘the University of Chicago’. Lefkofsky is also a celebrated writer having published his book: Accelerated Disruption.
Dr. Clay Siegall is one of the most influential figures in the oncology world. He is known to many as the chief executive officer, founder, and chairman of a biotechnology company known as Seattle Genetics. The company specializes in developing therapy drugs for individuals living with cancer. The treatments developed by the company have reduced the mortality rates for cancer in different countries.
Clay Siegall studied zoology at the prestigious University of Maryland. Later on, he went for his Ph.D. studies at the famous George Washington University. The knowledge he acquired from this learning institutions has played a key role in his success.
As the chief executive officer and chairman of Seattle Genetics, Clay Siegall has been influential in leading the firm in discovering new cancer treatments. The company has already managed to market its FDA approved drug conjugate, known as ADCETRIS. The drug is used all over the world, and it has helped many people who had different types of cancer. The private company has also announced that it is planning to introduce more cancer therapies in the recent future.
Although Seattle Genetics was a tiny startup when it was established several years ago, Clay Siegall has contributed and worked hard to make it a better and respected center of cancer research. The company had very few researchers at first, but it gives employment opportunities to some of the most respected professionals in oncology today. Siegall says that he still has great plans for his company.
Since childhood, Siegall was always interested in business. He had a passion for the power demonstrated in technology, and he wanted to use it to overcome the disease. After going to school, he chose to intervene in nature and restore the health of patients who were destined to die. At first, he specialized in cancer therapies. This is because one of his close family members had cancer, and the treatment he was receiving was brutal. The treatment resulted to severe anemia. Siegall says that he almost lost the patient because of the chemotherapy treatment. The respected scientist says that he was also interested in the money that comes with establishing a company. Clay had worked as a senior professor for a while, and the amount he was paid was little.
Recently, Cancer Treatment Centers of America (CTCA) have announced an addition added to their NantHealth computer software. Clinical Pathways, featuring eviti is the latest in integrated health services for cancer patients. Clinical Pathways have been developed with a full library of over 2700 cancer treatment and varying degrees of treatment options for all types of cancer. Clinical Pathways is able to set a customized plan of treatment with different treatment options for each patient.
As stated in the article, “Cancer Treatment Centers of America® Partners with Allscripts and NantHealth to Launch Clinical Pathways, a Comprehensive and Custom Oncology Treatment Platform,” Clinical Pathways have been developed from the latest in reviewed cancer literature, government agencies, and oncology associations and is maintained by a full time team of Oncologists, Oncology nurses, and a group of Oncology experts. The system takes the guess work out of treatment options and works with the Oncologist without interrupting the Doctor’s electronic patient care records. All of the research, treatment options, and proposed different levels of care are available instantly to the Oncologist. Click here and Learn more.
The Clinical Pathways system is available for use with all five Cancer Treatment Centers of America. CTCA is based out of Boca Raton, Florida, and specializes in the treatment of adults with cancer. CTCA offers a “full” body approach when treating patients. CTCA will treat the body and mind simultaneously believing that the body will heal faster when all body systems are provided for.
This holistic way of treating patients has yielded a high success rate for both the staff and the patients. At CTCA, they treat each patient like the individual they are, tailoring treatments to the patient’s cancer. They will also monitor and treat the patient for any acquired side effects such as nausea, or dizziness.
For further information on CTCA follow them on Twitter.